VIR 201

Drug Profile

VIR 201

Alternative Names: Co-X-Gene HIV vaccine; VIR201

Latest Information Update: 24 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Virax Holdings
  • Developer Australian National University; Prescient Therapeutics
  • Class AIDS vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 19 Jul 2007 Clinical data added to the adverse events and Viral Infections immunogenicity sections ,,
  • 21 Nov 2006 The US FDA has approved the IND application for a phase II trial of VIR 201 in the US
  • 25 Oct 2006 Virax has filed an IND with the FDA in the United States for HIV Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top